Thermo Fisher Scientific | TMO - Cash And Equivalent


Thermo Fisher Scientific reported $3.25B in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Abbott USD 6.8B 1.72B Mar/2026
Agilent USD 1.81B 49M Mar/2026
Becton, Dickinson and Co. USD 813M 73M Mar/2026
Bio Techne USD 209.82M 36.94M Mar/2026
Bio-Rad Laboratories USD 507.2M 22.6M Mar/2026
Boston Scientific USD 1.45B 512M Mar/2026
Bruker USD 133.4M 165.4M Mar/2026
Charles River Laboratories USD 191.83M 21.94M Mar/2026
Danaher USD 5.7B 1.09B Mar/2026
Dentsply International USD 190M 136M Mar/2026
Edwards Lifesciences USD 2.4B 538M Mar/2026
General Electric Aerospace USD 9.35B 1.64B Jun/2026
Henry Schein USD 138M 18M Mar/2026
Illumina USD 1.42B 368M Dec/2025
Intuitive Surgical USD 8.63B 646.3M Jun/2026
IQVIA Holdings USD 1.95B 33M Mar/2026
Laboratory Of America USD 981.1M 448.8M Mar/2026
Medtronic USD 1.15B 135M Dec/2025
Mettler Toledo International USD 66.89M 2.18M Dec/2025
Myriad Genetics USD 124.4M 25.2M Mar/2026
Olympus JPY 147.24B 93.98B Sep/2025
OraSure Technologies USD 176.96M 22.31M Mar/2026
Quest Diagnostics USD 393M 27M Mar/2026
Repligen USD 582.65M 16.63M Mar/2026
Revvity USD 860.32M 59.54M Mar/2026
Stryker USD 2.88B 1.13B Mar/2026
Thermo Fisher Scientific USD 3.25B 6.6B Mar/2026
Veracyte USD 263.14M 99.44M Mar/2026
Waters USD 462M 125.83M Mar/2026
Zimmer Biomet Holdings USD 424.2M 167.7M Mar/2026